AVALO THERAPEUTICS, INC. (AVTX) Total liabilities 2016–2025
AVALO THERAPEUTICS, INC. (AVTX) total liabilities at each fiscal year-end, per SEC filings.
$33.4MFY2025 · since FY2016: $5.6M → $33.4M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $33.4M | +88.8% |
| FY2024 | $17.7M | +29.3% |
| FY2023 | $13.7M | -69.1% |
| FY2022 | $44.3M | -22.5% |
| FY2021 | $57.1M | +197.7% |
| FY2020 | $19.2M | +27.0% |
| FY2019 | $15.1M | -69.4% |
| FY2018 | $49.3M | +230.1% |
| FY2017 | $14.9M | +168.7% |
| FY2016 | $5.6M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More AVTX financial trends
AVTX RevenueAVTX Net incomeAVTX Net marginAVTX Gross profitAVTX Gross marginAVTX Operating incomeAVTX Operating marginAVTX Operating cash flowAVTX Free cash flowAVTX Capital expendituresAVTX Return on equityAVTX Stock buybacksAVTX Dividends paidAVTX Total assetsAVTX Shareholders’ equityAVTX overview →